Account
Articles
29.05.2019
What are precision medicines

What is the future of precision medicine in the EU? The field of precision medicine is a complex are...

Read more
News
30.04.2019
How pharmacist biosimilar substitution would work

The law provides a legal framework for the automatic substitution of biosimilars at the level of the...

Read more
News
29.03.2019
Canadian government to make prescriptions more aff

Canadians pay too much for prescription drugs – and that means far too many go without the medicin...

Read more
News
20.03.2019
NICE approve Almirall's Ilumetri

Initially NICE rejected Illumetri for not being cost-effective, but a new negotiated price means th...

Read more
News
19.03.2019
NICE suggest industry must align

Speaking at the international pharma conference, NICE’s chief executive Sir Andrew Dillon struck a...

Read more
News
15.03.2019
SMC says no to Novartis' Kymriah

Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scot...

Read more
News
13.03.2019
Myeloma drug combo approved

A new game changing treatment for people with multiple myeloma will now be available on the NHS in E...

Read more
Articles
07.03.2019
NICE evidence request for Blincyto

Conclusion: Blincyto has significant clinical benefits, but that further evidence on cost-effective...

Read more
Case Studies
21.09.2018
Payer value proposition development

Understanding payer value and evidence requirements to secure pricing and reimbursement for a novel ...

Read more
Articles
07.06.2018
Addressing antimicrobial resistance (AMR)

At the current rate, annual deaths due to AMR is expected to reach 10 million by 2050 globally, with...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.